Optimal timing of adjuvant treatment in patients with early breast cancer.
It is well established that adjuvant treatment reduces mortality after early breast cancer. However, the optimal timing of adjuvant treatment is not well described. To determine the optimal timing of adjuvant treatment, 402 breast cancer patients who received adjuvant treatment at Ankara Oncology Research and Training Hospital between January 1995 and August 2002 were evaluated retrospectively. Three hundred and fifty-seven (88.8%) patients received adjuvant chemotherapy, 204 (50.7%) of these patients received only adjuvant chemotherapy and 153 (38%) patients received tamoxifen following chemotherapy. Remaining 45 (11.2%) patients received only adjuvant tamoxifen. The median time to start adjuvant treatment after surgery was day 21 (range, days 4 to days 258), and the median follow-up was 50 months (range, 6-105 months). The patients were divided into 5 groups according to starting time of chemotherapy (shorter than 14 days, between days 15-29, between days 30-44, between days 45.-59 and more than 59 days). Overall survival (OS) and disease-free survival (DFS) were not shown significantly different between for 5 groups (P>0.05). Secondly, patients were divided into two groups as starting adjuvant treatment equal to or shorter than 44 days and longer than 44 days (n=344, 85.6% and vs. n=58, 14.4%, respectively). OS was significantly better in patients who started to receive adjuvant treatment within 44 days after surgery compared to patients who received adjuvant treatment after 44 days (92 vs. 83.3%, P=0.03) for 5 years, but DFS was not significantly different between two groups (83.4 vs. 82.2%, P>0.05). According to our study, adjuvant treatment of breast cancer should be initiated earlier after surgery.
Alkis
Necati
N
Department of Medical Oncology, Ankara Oncology Research and Training Hospital, and Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.
Durnali
Ayse G
AG
Arslan
Ulku Y
UY
Kocer
Murat
M
Onder
Fatih O
FO
Tokluoglu
Saadet
S
Celenkoglu
Gokhan
G
Muallaoglu
Sadik
S
Utkan
Gungor
G
Ulas
Arife
A
Altundag
Kadri
K
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D017024:Chemotherapy, Adjuvant / Q000379:methods*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008408:Mastectomy; D008875:Middle Aged; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage; D013629:Tamoxifen / Q000008:administration & dosage; D055815:Young Adult
D000970:Antineoplastic Agents; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen
Cancer Res. 1989 Apr 15;49(8):1996-2001
2702641
Langenbecks Arch Surg. 2002 Jul;387(3-4):109-116
12269263
Ann Oncol. 2000 Sep;11(9):1209
11061622
Semin Oncol. 2003 Oct;30(5 Suppl 16):21-9
14613023
Cancer. 2002 Jan 15;94(2):314-22
11900217
N Engl J Med. 1988 Sep 15;319(11):677-83
2901037
Cancer Res. 1989 Apr 15;49(8):2002-4
2522814
J Clin Oncol. 1994 May;12(5):888-94
8164038
Ann Oncol. 2005;16 Suppl 1:i7-9
15888763
Eur J Cancer. 2001 Nov;37(17):2184-93
11677105
Lancet. 1995 Nov 18;346(8986):1334-5
7475773
J Clin Oncol. 1995 Nov;13(11):2712-21
7595729
J Clin Oncol. 2000 Feb;18(3):584-90
10653873
J Clin Oncol. 2003 Oct 15;21(20):3792-7
14551298
Clin Breast Cancer. 2003 Oct;4(4):264-72
14651771
N Engl J Med. 2003 Jun 12;348(24):2431-42
12802030
Am J Clin Oncol. 1989 Dec;12(6):481-5
2589228
Ann Oncol. 2001 Apr;12(4):525-33
11398888
J Natl Cancer Inst. 1993 Jun 16;85(12):965-70
8496982